Cocrystal Pharma FY2024 net loss $17.5M; cash $9.9M; pipeline advances

Cocrystal Pharma, Inc.

2025-Q1 EPS reported -$0.23

Net loss of $17.5M ($1.72 per share) for FY2024, vs. $18.0M ($1.87) in 2023; R&D expenses $12.5M.
Cash and equivalents $9.9M as of Dec 31 2024, down from $26.4M a year earlier; working capital $9.2M.
Plans to initiate norovirus human challenge study in U.S. in 2025 for oral pan-viral protease inhibitor CDI-988.
Will continue Phase 2a influenza challenge study of CC-42344 after low infection rate precluded efficacy data.
Expects topline results from CDI-988 high-dose cohort in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.